彥臣生技藥品股份有限公司                                  
                                    股 東 權 益 變 動 表                                    
                     中華民國一○一年及一○○年一月一日至十二月三十一日                    
                                                                            單位:新台幣仟元
項    目            普通股股本    資本公積    法定盈餘公積    未提撥保留盈餘    股東權益合計
--------------------------------------------------------------------------------------------
100年度                                                                                     
期初餘額             $209,450      $6,569               -            $7,910        $223,929 
員工認股權行使          4,350       1,305               -                 -           5,655 
本期損益                    -           -               -             9,340           9,340 
盈餘指撥及分配                                                                              
提列法定盈餘公積            -           -             791              (791)              - 
--------------------------------------------------------------------------------------------
期末餘額             $213,800      $7,874            $791           $16,459        $238,924 
============================================================================================

項    目            普通股股本    資本公積    法定盈餘公積    未提撥保留盈餘    股東權益合計
--------------------------------------------------------------------------------------------
101年度                                                                                     
期初餘額             $213,800      $7,874            $791           $16,459        $238,924 
本期損益                    -           -               -           (17,203)        (17,203)
盈餘指撥及分配                                                                              
提列法定盈餘公積            -           -             934              (934)              - 
--------------------------------------------------------------------------------------------
期末餘額             $213,800      $7,874          $1,725           ($1,678)       $221,721 
============================================================================================